Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 5458178, 9 pages
https://doi.org/10.1155/2017/5458178
Review Article

Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells

Department of Life Science, Sogang University, 35 Baekbeom-ro, Mapo-gu, Seoul 04107, Republic of Korea

Correspondence should be addressed to Gap Ryol Lee; rk.ca.gnagos@eelrg

Received 31 October 2017; Revised 11 December 2017; Accepted 12 December 2017; Published 31 December 2017

Academic Editor: Qingdong Guan

Copyright © 2017 Gap Ryol Lee. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, “Foxp3 programs the development and function of CD4+CD25+ regulatory T cells,” Nature Immunology, vol. 4, no. 4, pp. 330–336, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Hori, T. Nomura, and S. Sakaguchi, “Control of regulatory T cell development by the transcription factor Foxp3,” Science, vol. 299, no. 5609, pp. 1057–1061, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. D. A. Vignali, L. W. Collison, and C. J. Workman, “How regulatory T cells work,” Nature Reviews Immunology, vol. 8, no. 7, pp. 523–532, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Hanahan and L. M. Coussens, “Accessories to the crime: functions of cells recruited to the tumor microenvironment,” Cancer Cell, vol. 21, no. 3, pp. 309–322, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Joyce and J. W. Pollard, “Microenvironmental regulation of metastasis,” Nature Reviews Cancer, vol. 9, no. 4, pp. 239–252, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Lindau, P. Gielen, M. Kroesen, P. Wesseling, and G. J. Adema, “The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells,” Immunology, vol. 138, no. 2, pp. 105–115, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. T. J. Curiel, G. Coukos, L. Zou et al., “Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival,” Nature Medicine, vol. 10, no. 9, pp. 942–949, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Leffers, M. J. M. Gooden, R. A. de Jong et al., “Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer,” Cancer Immunology, Immunotherapy, vol. 58, no. 3, pp. 449–459, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Tao, Y. Mimura, K. Aoe et al., “Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells,” Lung Cancer, vol. 75, no. 1, pp. 95–101, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Jiang, Z. Du, F. Yang et al., “FOXP3+ lymphocyte density in pancreatic cancer correlates with lymph node metastasis,” PLoS One, vol. 9, no. 9, article e106741, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Tang, X. Xu, S. Guo et al., “An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma,” PLoS One, vol. 9, no. 3, article e91551, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. Z. Yang, A. J. Novak, M. J. Stenson, T. E. Witzig, and S. M. Ansell, “Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma,” Blood, vol. 107, no. 9, pp. 3639–3646, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. E. J. Sayour, P. McLendon, R. McLendon et al., “Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma,” Cancer Immunology, Immunotherapy, vol. 64, no. 4, pp. 419–427, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. R. J. deLeeuw, S. E. Kost, J. A. Kakal, and B. H. Nelson, “The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature,” Clinical Cancer Research, vol. 18, no. 11, pp. 3022–3029, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Shang, Y. Liu, and S. J. Jiang, “Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis,” Scientific Reports, vol. 5, no. 1, p. 15179, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Salama, M. Phillips, F. Grieu et al., “Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 2, pp. 186–192, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Badoual, S. Hans, J. Rodriguez et al., “Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers,” Clinical Cancer Research, vol. 12, no. 2, pp. 465–472, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Haas, A. Dimmler, W. Hohenberger, G. G. Grabenbauer, G. Niedobitek, and L. V. Distel, “Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia,” BMC Gastroenterology, vol. 9, no. 1, p. 65, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Ladoire, F. Martin, and F. Ghiringhelli, “Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer,” Cancer Immunology, Immunotherapy, vol. 60, no. 7, pp. 909–918, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Trinchieri, “Cancer and inflammation: an old intuition with rapidly evolving new concepts,” Annual Review of Immunology, vol. 30, no. 1, pp. 677–706, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. W. H. Fridman, L. Zitvogel, C. Sautes-Fridman, and G. Kroemer, “The immune contexture in cancer prognosis and treatment,” Nature Reviews. Clinical Oncology, vol. 14, no. 12, pp. 717–734, 2017. View at Publisher · View at Google Scholar
  22. T. Saito, H. Nishikawa, H. Wada et al., “Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers,” Nature Medicine, vol. 22, no. 6, pp. 679–684, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. A. W. Mailloux and M. R. Young, “Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression,” Critical Reviews in Immunology, vol. 30, no. 5, pp. 435–447, 2010. View at Publisher · View at Google Scholar
  24. M. Gobert, I. Treilleux, N. Bendriss-Vermare et al., “Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome,” Cancer Research, vol. 69, no. 5, pp. 2000–2009, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Ishida, T. Ishii, A. Inagaki et al., “Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege,” Cancer Research, vol. 66, no. 11, pp. 5716–5722, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Pere, Y. Montier, J. Bayry et al., “A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens,” Blood, vol. 118, no. 18, pp. 4853–4862, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. M. C. Tan, P. S. Goedegebuure, B. A. Belt et al., “Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer,” Journal of Immunology, vol. 182, no. 3, pp. 1746–1755, 2009. View at Publisher · View at Google Scholar
  28. A. Facciabene, X. Peng, I. S. Hagemann et al., “Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells,” Nature, vol. 475, no. 7355, pp. 226–230, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Pedroza-Gonzalez, C. Verhoef, J. N. Ijzermans et al., “Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer,” Hepatology, vol. 57, no. 1, pp. 183–194, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Malchow, D. S. Leventhal, S. Nishi et al., “Aire-dependent thymic development of tumor-associated regulatory T cells,” Science, vol. 339, no. 6124, pp. 1219–1224, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Wang, F. Franco, and P. C. Ho, “Metabolic regulation of Tregs in cancer: opportunities for immunotherapy,” Trends in Cancer, vol. 3, no. 8, pp. 583–592, 2017. View at Publisher · View at Google Scholar
  32. P. C. Ho, J. D. Bihuniak, A. N. Macintyre et al., “Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses,” Cell, vol. 162, no. 6, pp. 1217–1228, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. C. H. Chang, J. Qiu, D. O’Sullivan et al., “Metabolic competition in the tumor microenvironment is a driver of cancer progression,” Cell, vol. 162, no. 6, pp. 1229–1241, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. K. E. Scott and J. L. Cleveland, “Lactate wreaks havoc on tumor-infiltrating T and NK cells,” Cell Metabolism, vol. 24, no. 5, pp. 649-650, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. D. E. Speiser, P. C. Ho, and G. Verdeil, “Regulatory circuits of T cell function in cancer,” Nature Reviews Immunology, vol. 16, no. 10, pp. 599–611, 2016. View at Publisher · View at Google Scholar · View at Scopus
  36. N. J. MacIver, R. D. Michalek, and J. C. Rathmell, “Metabolic regulation of T lymphocytes,” Annual Review of Immunology, vol. 31, no. 1, pp. 259–283, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. R. D. Michalek, V. A. Gerriets, S. R. Jacobs et al., “Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets,” The Journal of Immunology, vol. 186, no. 6, pp. 3299–3303, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Fischer, P. Hoffmann, S. Voelkl et al., “Inhibitory effect of tumor cell-derived lactic acid on human T cells,” Blood, vol. 109, no. 9, pp. 3812–3819, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Huber, C. Camisaschi, A. Berzi et al., “Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation,” Seminars in Cancer Biology, vol. 43, pp. 74–89, 2017. View at Publisher · View at Google Scholar
  40. A. Angelin, L. Gil-de-Gómez, S. Dahiya et al., “Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments,” Cell Metabolism, vol. 25, no. 6, pp. 1282–1293.e7, 2017. View at Publisher · View at Google Scholar
  41. G. Plitas, C. Konopacki, K. Wu et al., “Regulatory T cells exhibit distinct features in human breast cancer,” Immunity, vol. 45, no. 5, pp. 1122–1134, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Nizar, B. Meyer, C. Galustian, D. Kumar, and A. Dalgleish, “T regulatory cells, the evolution of targeted immunotherapy,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1806, no. 1, pp. 7–17, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. D. Gabrilovich, “Mechanisms and functional significance of tumour-induced dendritic-cell defects,” Nature Reviews Immunology, vol. 4, no. 12, pp. 941–952, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Zhou and H. I. Levitsky, “Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance,” The Journal of Immunology, vol. 178, no. 4, pp. 2155–2162, 2007. View at Publisher · View at Google Scholar
  45. A. Curti, S. Pandolfi, B. Valzasina et al., “Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25 into CD25+ T regulatory cells,” Blood, vol. 109, pp. 2871–2877, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. J. M. Weiss, A. M. Bilate, M. Gobert et al., “Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells,” The Journal of Experimental Medicine, vol. 209, no. 10, pp. 1723–1742, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. J. P. Hindley, C. Ferreira, E. Jones et al., “Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors,” Cancer Research, vol. 71, no. 3, pp. 736–746, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Sainz-Perez, A. Lim, B. Lemercier, and C. Leclerc, “The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences,” Cancer Research, vol. 72, no. 14, pp. 3557–3569, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Bu, Y. Shen, W. L. Seeger et al., “Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8+ T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression,” Tumour Biology, vol. 37, no. 3, pp. 3949–3956, 2016. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Wang, J. H. Lee, and C. H. Kim, “Optimal population of FoxP3+ T cells in tumors requires an antigen priming-dependent trafficking receptor switch,” PLoS One, vol. 7, no. 1, article e30793, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. G. M. Delgoffe, S. R. Woo, M. E. Turnis et al., “Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis,” Nature, vol. 501, no. 7466, pp. 252–256, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. K. Ali, D. R. Soond, R. Piñeiro et al., “Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer,” Nature, vol. 510, pp. 407–411, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. C. T. Luo, W. Liao, S. Dadi, A. Toure, and M. O. Li, “Graded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity,” Nature, vol. 529, no. 7587, pp. 532–536, 2016. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. Grinberg-Bleyer, H. Oh, A. Desrichard et al., “NF-κB c-Rel is crucial for the regulatory T cell immune checkpoint in cancer,” Cell, vol. 170, no. 6, pp. 1096–1108.e13, 2017. View at Publisher · View at Google Scholar
  55. H. Nakagawa, J. M. Sido, E. E. Reyes, V. Kiers, H. Cantor, and H. J. Kim, “Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 22, pp. 6248–6253, 2016. View at Publisher · View at Google Scholar · View at Scopus
  56. A. E. Overacre-Delgoffe, M. Chikina, R. E. Dadey et al., “Interferon-γ drives T reg fragility to promote anti-tumor immunity,” Cell, vol. 169, no. 6, pp. 1130–1141.e11, 2017. View at Publisher · View at Google Scholar
  57. M. De Simone, A. Arrigoni, G. Rossetti et al., “Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells,” Immunity, vol. 45, no. 5, pp. 1135–1147, 2016. View at Publisher · View at Google Scholar · View at Scopus
  58. D. Burzyn, W. Kuswanto, D. Kolodin et al., “A special population of regulatory T cells potentiates muscle repair,” Cell, vol. 155, no. 6, pp. 1282–1295, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Scurr, K. Ladell, M. Besneux et al., “Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3 T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells,” Mucosal Immunology, vol. 7, no. 2, pp. 428–439, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. N. Kakita, T. Kanto, I. Itose et al., “Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25 FOXP3 T cells,” International Journal of Cancer, vol. 131, no. 11, pp. 2573–2583, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Amedei, E. Niccolai, M. Benagiano et al., “Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions,” Cancer Immunology, Immunotherapy, vol. 62, no. 7, pp. 1249–1260, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Yi, H. W. He, J. X. Wang et al., “The functional impairment of HCC-infiltrating γδ T cells, partially mediated by regulatory T cells in a TGFβ- and IL-10-dependent manner,” Journal of Hepatology, vol. 58, no. 5, pp. 977–983, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Yan, Y. Zhang, J. P. Zhang, J. Liang, L. Li, and L. Zheng, “Tim-3 expression defines regulatory T cells in human tumors,” PLoS One, vol. 8, no. 3, article e58006, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. J. D. Bui, R. Uppaluri, C. S. Hsieh, and R. D. Schreiber, “Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins,” Cancer Research, vol. 66, no. 14, pp. 7301–7309, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. C. A. Bauer, E. Y. Kim, F. Marangoni, E. Carrizosa, N. M. Claudio, and T. R. Mempel, “Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction,” The Journal of Clinical Investigation, vol. 124, no. 6, pp. 2425–2440, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. T. L. Whiteside, “The role of regulatory T cells in cancer immunology,” ImmunoTargets and Therapy, vol. 4, pp. 159–171, 2015. View at Publisher · View at Google Scholar
  67. U. Grohmann, C. Orabona, F. Fallarino et al., “CTLA-4-Ig regulates tryptophan catabolism in vivo,” Nature Immunology, vol. 3, no. 11, pp. 1097–1101, 2002. View at Publisher · View at Google Scholar · View at Scopus
  68. J. D. Mezrich, J. H. Fechner, X. Zhang, B. P. Johnson, W. J. Burlingham, and C. A. Bradfield, “An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells,” The Journal of Immunology, vol. 185, no. 6, pp. 3190–3198, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. F. Fallarino, U. Grohmann, S. You et al., “The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells,” The Journal of Immunology, vol. 176, no. 11, pp. 6752–6761, 2006. View at Publisher · View at Google Scholar
  70. D. A. Wainwright, I. V. Balyasnikova, A. L. Chang et al., “IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival,” Clinical Cancer Research, vol. 18, no. 22, pp. 6110–6121, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Pere, C. Tanchot, J. Bayry et al., “Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer,” OncoImmunology, vol. 1, no. 3, pp. 326–333, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. B. Chaudhary and E. Elkord, “Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting,” Vaccines, vol. 4, no. 3, p. 28, 2016. View at Publisher · View at Google Scholar
  73. J. H. Sampson, R. J. Schmittling, G. E. Archer et al., “A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma,” PLoS One, vol. 7, no. 2, article e31046, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. A. J. Rech, R. Mick, S. Martin et al., “CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients,” Science Translational Medicine, vol. 4, no. 134, article 134ra62, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. J. F. Jacobs, C. J. Punt, W. J. Lesterhuis et al., “Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients,” Clinical Cancer Research, vol. 16, no. 20, pp. 5067–5078, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. J. Dannull, Z. Su, D. Rizzieri et al., “Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells,” The Journal of Clinical Investigation, vol. 115, no. 12, pp. 3623–3633, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. P. Attia, A. V. Maker, L. R. Haworth, L. Rogers-Freezer, and S. A. Rosenberg, “Inability of a fusion protein of IL-2 and diphtheria toxin (denileukin diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma,” Journal of Immunotherapy, vol. 28, no. 6, pp. 582–592, 2005. View at Publisher · View at Google Scholar
  78. F. Arce Vargas, A. J. S. Furness, I. Solomon et al., “Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors,” Immunity, vol. 46, no. 4, pp. 577–586, 2017. View at Publisher · View at Google Scholar
  79. E. I. Buchbinder and A. Desai, “CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition,” American Journal of Clinical Oncology, vol. 39, no. 1, pp. 98–106, 2016. View at Publisher · View at Google Scholar · View at Scopus
  80. J. D. Wolchok, H. Kluger, M. K. Callahan et al., “Nivolumab plus ipilimumab in advanced melanoma,” The New England Journal of Medicine, vol. 369, no. 2, pp. 122–133, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. S. L. Topalian, M. Sznol, D. F. McDermott et al., “Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab,” Journal of Clinical Oncology, vol. 32, no. 10, pp. 1020–1030, 2014. View at Publisher · View at Google Scholar · View at Scopus
  82. M. A. Postow, M. K. Callahan, and J. D. Wolchok, “Immune checkpoint blockade in cancer therapy,” Journal of Clinical Oncology, vol. 33, no. 17, pp. 1974–1982, 2015. View at Publisher · View at Google Scholar · View at Scopus
  83. S. M. Ansell, A. M. Lesokhin, I. Borrello et al., “PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma,” The New England Journal of Medicine, vol. 372, no. 4, pp. 311–319, 2015. View at Publisher · View at Google Scholar · View at Scopus
  84. B. Kavanagh, S. O'Brien, D. Lee et al., “CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion,” Blood, vol. 112, no. 4, pp. 1175–1183, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. A. V. Maker, P. Attia, and S. A. Rosenberg, “Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade,” The Journal of Immunology, vol. 175, no. 11, pp. 7746–7754, 2005. View at Publisher · View at Google Scholar
  86. D. O'Mahony, J. C. Morris, C. Quinn et al., “A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy,” Clinical Cancer Research, vol. 13, no. 3, pp. 958–964, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. C. Ralph, E. Elkord, D. J. Burt et al., “Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma,” Clinical Cancer Research, vol. 16, no. 5, pp. 1662–1672, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. J. S. Weber, O. Hamid, S. D. Chasalow et al., “Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma,” Journal of Immunotherapy, vol. 35, no. 1, pp. 89–97, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. T. R. Simpson, F. Li, W. Montalvo-Ortiz et al., “Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma,” The Journal of Experimental Medicine, vol. 210, no. 9, pp. 1695–1710, 2013. View at Publisher · View at Google Scholar · View at Scopus
  90. K. Ko, S. Yamazaki, K. Nakamura et al., “Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells,” The Journal of Experimental Medicine, vol. 202, no. 7, pp. 885–891, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. J. Mitsui, H. Nishikawa, D. Muraoka et al., “Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals,” Clinical Cancer Research, vol. 16, no. 10, pp. 2781–2791, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Piconese, B. Valzasina, and M. P. Colombo, “OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection,” The Journal of Experimental Medicine, vol. 205, no. 4, pp. 825–839, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. A. M. Lesokhin, M. K. Callahan, M. A. Postow, and J. D. Wolchok, “On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation,” Science Translational Medicine, vol. 7, no. 280, p. 280sr1, 2015. View at Publisher · View at Google Scholar · View at Scopus
  94. N. A. Taylor, S. C. Vick, M. D. Iglesia et al., “Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer,” The Journal of Clinical Investigation, vol. 127, no. 9, pp. 3472–3483, 2017. View at Publisher · View at Google Scholar
  95. B. Ondondo, E. Jones, A. Godkin, and A. Gallimore, “Home sweet home: the tumor microenvironment as a haven for regulatory T cells,” Frontiers in Immunology, vol. 4, p. 197, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. K. Kurose, Y. Ohue, E. Sato et al., “Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760),” Journal of Thoracic Oncology, vol. 10, no. 1, pp. 74–83, 2015. View at Publisher · View at Google Scholar · View at Scopus
  97. T. Ishida, T. Joh, N. Uike et al., “Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study,” Journal of Clinical Oncology, vol. 30, no. 8, pp. 837–842, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. N. Redjimi, C. Raffin, I. Raimbaud et al., “CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity,” Cancer Research, vol. 72, no. 17, pp. 4351–4360, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. R. S. Muraoka, N. Dumont, C. A. Ritter et al., “Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases,” The Journal of Clinical Investigation, vol. 109, no. 12, pp. 1551–1559, 2002. View at Publisher · View at Google Scholar
  100. L. Gorelik and R. A. Flavell, “Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells,” Nature Medicine, vol. 7, no. 10, pp. 1118–1122, 2001. View at Publisher · View at Google Scholar · View at Scopus
  101. Z. Sun, J. Fourcade, O. Pagliano et al., “IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells,” Cancer Research, vol. 75, no. 8, pp. 1635–1644, 2015. View at Publisher · View at Google Scholar · View at Scopus
  102. A. P. Vicari, C. Chiodoni, C. Vaure et al., “Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody,” The Journal of Experimental Medicine, vol. 196, no. 4, pp. 541–549, 2002. View at Publisher · View at Google Scholar · View at Scopus
  103. M. E. Turnis, D. V. Sawant, A. L. Szymczak-Workman et al., “Interleukin-35 limits anti-tumor immunity,” Immunity, vol. 44, no. 2, pp. 316–329, 2016. View at Publisher · View at Google Scholar · View at Scopus